Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Plenary Session Abstracts

Plenary Session Abstracts

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
Thomas Powles, Se Hoon Park, Eric Voog, et al.
 
 
 
Watch also the ecancer interview with Prof Thomas Powles - Barts Cancer Institute, London, UK

--------------------------------------------------------------------------------------------------------------------------------------------------------

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Seema Ahsan Khan, Fengmin Zhao, Lawrence J. Solin, et al.
 
 

--------------------------------------------------------------------------------------------------------------------------------------------------------

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Shaji Kumar, Susanna J. Jacobus, Adam D. Cohen, et al.

 

--------------------------------------------------------------------------------------------------------------------------------------------------------

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study
Thierry Andre, Kai-Keen Shiu, Tae Won Kim, et al.
 
 

--------------------------------------------------------------------------------------------------------------------------------------------------------

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Roy S. Herbst, Masahiro Tsuboi, Thomas John, et al.
 
 
 
Watch also the ecancer interview with Prof Roy Herbst - Yale Cancer Center, New Haven, USA
 

CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting - view slide set:

Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC